Trial Profile
A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer (NSCLC) (DESTINY-Lung01)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms DESTINY-Lung01
- Sponsors Daiichi Sankyo Inc
- 29 Jan 2024 According to Daiichi Sankyo Company Media Release, sBLA is being reviewed under Real-Time Oncology Review (RTOR) programme and Project Orbis, two initiatives of FDA which are designed to bring safe and effective cancer treatments to patients as early as possible. The FDA has granted the application Priority Review in the US.
- 24 Oct 2023 Results (n=90) assessing associations between baseline gene mutations using ctDNA and clinical outcomes in these patients presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress